Quantitative Investment Management LLC Purchases 4,124 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Quantitative Investment Management LLC grew its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 106.9% during the second quarter, Holdings Channel reports. The fund owned 7,981 shares of the biopharmaceutical company’s stock after purchasing an additional 4,124 shares during the period. Quantitative Investment Management LLC’s holdings in Alnylam Pharmaceuticals were worth $2,402,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ALNY. iA Global Asset Management Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 979.5% during the 4th quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock valued at $7,070,000 after buying an additional 16,133 shares in the last quarter. SCS Capital Management LLC bought a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter worth about $34,784,000. Hussman Strategic Advisors Inc. bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $2,505,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at about $50,773,000. Finally, Hsbc Holdings PLC lifted its position in Alnylam Pharmaceuticals by 22.6% during the 4th quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock valued at $35,675,000 after acquiring an additional 16,503 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $237.10 on Monday. Alnylam Pharmaceuticals, Inc. has a one year low of $197.81 and a one year high of $495.55. The business’s fifty day moving average is $262.62 and its 200 day moving average is $293.54. The stock has a market capitalization of $31.73 billion, a PE ratio of 44.07 and a beta of 0.30. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. The business had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.Alnylam Pharmaceuticals’s revenue was up 66.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.51) EPS. On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current year.

Analyst Ratings Changes

ALNY has been the topic of a number of recent research reports. Chardan Capital restated a “buy” rating and issued a $425.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, July 31st. Royal Bank Of Canada lowered their target price on shares of Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Truist Financial dropped their price target on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating on the stock in a research report on Tuesday, August 4th. BMO Capital Markets assumed coverage on Alnylam Pharmaceuticals in a research note on Wednesday, August 19th. They issued an “outperform” rating and a $318.00 price target on the stock. Finally, Barclays reduced their price objective on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a research report on Monday, August 3rd. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $386.14.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.